During the past decade, Osaka Medical Center for Cancer and Cardiovascular Diseases conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 9 clinical trials were completed, i.e. on average, 64.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 6 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Osaka Medical Center for Cancer and Cardiovascular Diseases" #1 sponsor was "EMD Serono Research & Development Institute, Inc." with 3 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Daiichi Sankyo, Inc." with 2 trials sponsored, "Nobelpharma" with 2 trials sponsored and "Osaka Medical Center for Cancer and Cardiovascular Diseases" with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Osaka Medical Center for Cancer and Cardiovascular Diseases" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "ADIR, a Servier Group company" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "European Society of Surgical Oncology" with 1 trials as a collaborator and "Japan Clinical Oncology Group" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Osaka Medical Center for Cancer and Cardiovascular Diseases" are "Colorectal Cancer" (4 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Non-small Cell Lung Cancer" (2 trials), "Pancreatic Cancer" (2 trials) and "Zinc Deficiency" (2 trials). Many other conditions were trialed in "Osaka Medical Center for Cancer and Cardiovascular Diseases" in a lesser frequency.

Most popular intervention types in "Osaka Medical Center for Cancer and Cardiovascular Diseases" are "Drug" (25 trials), "Other" (3 trials), "Procedure" (2 trials), "Radiation" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Paclitaxel" (3 trials), "BBI608" (2 trials), "Gemcitabine" (2 trials) and "M7824" (2 trials). Other intervention names were less common.

The vast majority of trials in "Osaka Medical Center for Cancer and Cardiovascular Diseases" are 24 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Osaka Medical Center for Cancer and Cardiovascular Diseases". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Osaka Medical Center for Cancer and Cardiovascular Diseases, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Osaka Medical Center for Cancer and Cardiovascular Diseases, 2 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".

Osaka Medical Center for Cancer and Cardiovascular Diseases has several departments that took part in Clinical trials: "Osaka Medical Center for Cancer and Cardiovascular Diseases" - 10 trials, "Osaka International Cancer Institute" - 112 trials